200 related articles for article (PubMed ID: 31956364)
1. Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma.
Fu L; Cheng Z; Dong F; Quan L; Cui L; Liu Y; Zeng T; Huang W; Chen J; Pang Y; Ye X; Wu G; Qian T; Chen Y; Si C
J Cancer; 2020; 11(5):1182-1194. PubMed ID: 31956364
[No Abstract] [Full Text] [Related]
2. Increased expression of IFI16 predicts adverse prognosis in multiple myeloma.
Huang W; Qian T; Huang Z; Liu Y; Cui L; Zhu P; Zhong Q; Zeng T; Fu L; Si C; Deng C
Pharmacogenomics J; 2021 Aug; 21(4):520-532. PubMed ID: 33712724
[TBL] [Abstract][Full Text] [Related]
3. Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma.
Zhang W; Lin Y; Liu X; He X; Zhang Y; Fu W; Yang Z; Yang P; Wang J; Hu K; Zhang X; Liu W; Yuan X; Jing H
J Transl Med; 2018 Dec; 16(1):363. PubMed ID: 30563570
[TBL] [Abstract][Full Text] [Related]
4. Fc Fragment of IgE Receptor Ig (FCER1G) acts as a key gene involved in cancer immune infiltration and tumour microenvironment.
Yang R; Chen Z; Liang L; Ao S; Zhang J; Chang Z; Wang Z; Zhou Y; Duan X; Deng T
Immunology; 2023 Feb; 168(2):302-319. PubMed ID: 36054819
[TBL] [Abstract][Full Text] [Related]
5. Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma.
Xiang J; Chen X; Chen M; Hou J
Biomed Res Int; 2022; 2022():3307873. PubMed ID: 35372573
[TBL] [Abstract][Full Text] [Related]
6. Co-expression network analysis identified FCER1G in association with progression and prognosis in human clear cell renal cell carcinoma.
Chen L; Yuan L; Wang Y; Wang G; Zhu Y; Cao R; Qian G; Xie C; Liu X; Xiao Y; Wang X
Int J Biol Sci; 2017; 13(11):1361-1372. PubMed ID: 29209141
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of
Deng C; Si C; Ye X; Zhou Q; Zeng T; Huang Z; Huang W; Zhu P; Zhong Q; Wu Z; Zhu H; Lin Q; Zhang W; Fu L; Zheng Y; Qian T
J Cancer; 2021; 12(7):1936-1944. PubMed ID: 33753991
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive value of FCER1G in glioma outcomes and response to immunotherapy.
Xu H; Zhu Q; Tang L; Jiang J; Yuan H; Zhang A; Lou M
Cancer Cell Int; 2021 Feb; 21(1):103. PubMed ID: 33579299
[TBL] [Abstract][Full Text] [Related]
9. Increased Expression of SRSF1 Predicts Poor Prognosis in Multiple Myeloma.
Zhang J; Wang Z; Wang K; Xin D; Wang L; Fan Y; Xu Y
J Oncol; 2023; 2023():9998927. PubMed ID: 37206090
[TBL] [Abstract][Full Text] [Related]
10. Clinical prognostic implications of EPB41L4A expression in multiple myeloma.
Zhang W; Lai R; He X; Liu X; Zhang Y; Yang Z; Yang P; Wang J; Hu K; Yuan X; Zhang X; Liu W; Jing H
J Cancer; 2020; 11(3):619-629. PubMed ID: 31942185
[No Abstract] [Full Text] [Related]
11. High expression of CPNE5 and CPNE9 predicts positive prognosis in multiple myeloma.
Zhu P; Qian T; Si C; Liu Y; Cui L; Huang W; Fu L; Deng C; Zeng T
Cancer Biomark; 2021; 31(1):77-85. PubMed ID: 33780365
[TBL] [Abstract][Full Text] [Related]
12. High expression of CHML predicts poor prognosis of multiple myeloma.
Zhang W; Cao L; Liu X; He X; Zhang Y; Yang Z; Yang P; Wang J; Hu K; Zhang X; Liu W; Yuan X; Jing H
J Cancer; 2019; 10(24):6048-6056. PubMed ID: 31762814
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
Deng P; Zhou YL; Wei YL; Li P; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
[TBL] [Abstract][Full Text] [Related]
14. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
15. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
[TBL] [Abstract][Full Text] [Related]
16. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
17. High expression of UBE2T predicts poor prognosis and survival in multiple myeloma.
Zhang W; Zhang Y; Yang Z; Liu X; Yang P; Wang J; Hu K; He X; Zhang X; Jing H
Cancer Gene Ther; 2019 Nov; 26(11-12):347-355. PubMed ID: 30622320
[TBL] [Abstract][Full Text] [Related]
18. Genotype-immunophenotype analysis reveals the immunogenomic subtype and prognosis of multiple myeloma.
Wang Y; Feng W; Liu P
Carcinogenesis; 2020 Dec; 41(12):1746-1754. PubMed ID: 32278317
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of minichromosome maintenance family in multiple myeloma.
Quan L; Qian T; Cui L; Liu Y; Fu L; Si C
Cancer Gene Ther; 2020 Nov; 27(10-11):819-829. PubMed ID: 31959909
[TBL] [Abstract][Full Text] [Related]
20. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
